BARDA lifts stop work order on Vaxart norovirus trial; 10,000-participant screening to resume

Vaxart, Inc.

Stop work order lifted April 24, 2025 by ATI/BARDA; company may resume incurring costs.
Virtual meeting with BARDA confirmed Vaxart can proceed with screening 10,000 participants.
Company intends to reactivate field sites and screen participants for enrollment.
Discussions with BARDA ongoing regarding dosing plan, costs, timelines, and regulatory pathway.
Previously all work except per-protocol follow-up for 400-person cohort had been halted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.